<SEC-DOCUMENT>0001683168-19-003268.txt : 20191017
<SEC-HEADER>0001683168-19-003268.hdr.sgml : 20191017
<ACCEPTANCE-DATETIME>20191017093243
ACCESSION NUMBER:		0001683168-19-003268
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20191017
DATE AS OF CHANGE:		20191017

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-219589
		FILM NUMBER:		191154149

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>aethlon_424b3-219589.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)<BR>
Registration No. 333-219589</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUPPLEMENT NO. 5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(to prospectus dated November 29, 2018)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Prospectus Supplement No. 5
supplements and amends the prospectus dated November 29, 2018, or the Post-Effective Amendment Prospectus, relating to the
following common stock (numbers reflect pre 1-for-15 reverse stock split effected October 15, 2019) as originally
listed in the prospectus for which shares underlying warrants may be sold from time to time under the prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">5,454,546 Shares of Common Stock underlying
5,454,546 Common Warrants each to purchase 1 Share of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Up to 5,454,546 Pre-funded Units (each Pre-funded
Unit contains 1 Pre-funded Warrant to Purchase 1 Share of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and 1 Common Warrant to Purchase</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1 Share of Common Stock)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(5,454,546 Shares of Common Stock Underlying
the Pre-funded Warrants) and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(5,454,546 Shares of Common Stock Underlying
the Common Warrants)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>This prospectus supplement relates to
an existing registration of securities under Registration Statement File No. 333-219589, filed on November 29, 2018, and does not
cover securities beyond those covered by the existing Registration Statement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will not receive any proceeds from the
sale of these shares other than proceeds, if any, from the exercise of warrants to purchase shares of our common stock. If all
of the warrants are exercised for cash, we will receive a total of $6,000,000.00 in gross proceeds, which we expect to use for
general corporate purposes. We cannot assure you that any warrants will be exercised for cash. The selling stockholders may offer
and sell the shares covered by the prospectus as set forth in the prospectus. The stockholders may sell the shares directly or
through underwriters, brokers or dealers. The stockholders will bear any applicable sales commissions, transfer taxes and similar
expenses. We will pay all other expenses incident to the registration of the shares. See &ldquo;Plan of Distribution&rdquo; on
page 86 of the prospectus for more information on this topic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are filing this prospectus supplement
to supplement and amend the information previously included in the prospectus with the information contained in our Current Reports
on Form 8-K filed with the Securities and Exchange Commission on September 24, 2019, October 3, 2019 and October 15, 2019. Accordingly,
we have attached the referenced Current Reports on Form 8-K filed on September 24, 2019, October 3, 2019 and October 15, 2019 to
this prospectus supplement. This Prospectus Supplement No. 5 should be read in conjunction with, and delivered with, the Post-Effective
Amendment Prospectus and is qualified by reference to the Post-Effective Amendment Prospectus, except to the extent that the information
in this Prospectus Supplement No. 5 supersedes the information contained in the Post-Effective Amendment Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is traded on the Nasdaq
Capital Market under the symbol &ldquo;AEMD.&rdquo; On October 16, 2019, the last reported sale price of our common stock on the
Nasdaq Capital Market was $4.99 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Investing in our securities involves
significant risks, including those set forth in the &ldquo;Risk Factors&rdquo; section of the prospectus beginning at page 6.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NEITHER THE SECURITIES AND EXCHANGE COMMISSION
NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THE PROSPECTUS OR THIS PROSPECTUS
SUPPLEMENT IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement is
October 17, 2019.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>September 24, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>001-37487</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>13-3632859</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(IRS Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9635 Granite Ridge Drive, Suite 100</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Diego, California</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>92123</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Zip Code)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: 858-459-7800 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<U>see</U> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 96%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title of each class</FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Trading Symbol</FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common Stock</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AEMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 8.01</B></TD><TD><B>Other Events.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 24, 2019, the Company issued a press release announcing its collaboration to identify exosomes involved in cancer progression
and treatment resistance. The collaborator also announced the collaboration through its own press release. Copies of those press
releases are attached as Exhibit 99.1 hereto and are incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Description</U></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Releases dated September 24, 2019.</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Aethlon Medical, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: September 24, 2019</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 51%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ James B. Frakes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James B. Frakes</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Announces Collaboration to Identify
Exosomes Involved in Cancer Progression and Treatment Resistance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Exosome based liquid biopsies have
potential to transform cancer diagnostics and treatments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO (September 24, 2019) &ndash;
EXOSOME SCIENCES, a subsidiary of Aethlon Medical, Inc. (<B>Nasdaq: AEMD</B>), announced a research collaboration to identify and
characterize exosomes derived from patients with solid tumors such as pancreas cancer, as well as from families with genetically
high risk of developing cancer. These cancer-derived exosomes may serve as early markers for cancer diagnostics, cancer progression
and treatment resistance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information about this partnership please visit: https://www.hoag.org/news/hoag-to-study-unique-early-disease-markers/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ABOUT EXOSOME SCIENCES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exosome Sciences, Inc., a majority owned subsidiary of Aethlon
Medical, Inc., is a diagnostic company focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological
disease progression. Aethlon Medical, Inc. is a therapeutic company focused on addressing unmet needs in cancer and infectious
diseases. The Aethlon Hemopurifier&reg; is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening
viral infections. In cancer, the Hemopurifier&reg; depletes the presence of circulating tumor-derived exosomes that promote immune
suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The Hemopurifier&reg; is an FDA
designated &quot;Breakthrough Device&quot; related to the treatment of individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate
in the development or severity of the disease cancer. The Hemopurifier also holds a Breakthrough Device designation related to
life-threatening viruses that are not addressed with approved therapies. Additional information can be found online at www.AethlonMedical.com
and www.ExosomeSciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, that involve risks and uncertainties. Statements containing words such as &quot;may,&quot; &quot;believe,&quot; &quot;anticipate,&quot;
&quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;project,&quot; &quot;will,&quot; &quot;projections,&quot; &quot;estimate,&quot;
or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks
and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors
that may contribute to such differences include, without limitation, the Company's ability to raise additional funds and maintain
its listing on the Nasdaq Capital Market, or any other national securities exchange, the risk that the Company&rsquo;s collaborations
with hospitals will not be successful, that the Company&rsquo;s subsidiary will not be able to commercialize its products, that
the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's
products, the Company's ability to complete the development of the Hemopurifier and other planned products, the Company's ability
to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection
on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional
factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the
caption &quot;Risk Factors&quot; in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's
other filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. Except as may be required
by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">858-459-7800 x3300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Schull or Maggie Beller</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Russo Partners, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David.Schull@RussoPartnersLLC.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Maggie.Beller@RussoPartnersLLC.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">212-845-4271</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NEWPORT BEACH, CALIF., September 24, 2019 &ndash; </B>Hoag
Memorial Hospital Presbyterian announced today the start of a research study to identify and characterize potential early
disease markers for cancer diagnostics, cancer progression and treatment resistance.</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">In
partnership with Exosome Sciences, a subsidiary of Aethlon Medical, Inc. (Nasdaq: AEMD), scientists will study exosomes in
cancer patients and individuals at high genetic risk for cancer. Exosomes are nanoparticles that are abundantly released from
cancer cells and provide a snapshot of a tumor&rsquo;s genetic and protein cargo, making them important targets for
non-invasive liquid biopsies in cancer.</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&ldquo;Liquid
biopsies have the potential to facilitate the early detection of cancer and the assessment of the efficacy of potential
treatments in real time. This may prove to be a critical tool in our ongoing efforts to help patients with cancer,&rdquo;
said Michael Demeure, M.D., program director of Precision Medicine at Hoag&nbsp;and the principal investigator on the
study at Hoag. &ldquo;Hoag has an active&nbsp;Hereditary Cancer Program&nbsp;that supports a number of individuals and
families at high risk of developing cancer and is committed to achieving breakthroughs in the detection of cancer at its
earliest possible and most treatable stage.&rdquo;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&ldquo;Liquid
biopsies are a rapidly developing field of non-invasive tests for patients with and at risk for cancer,&rdquo; said Timothy Rodell,
M.D., CEO of Exosome Sciences and Aethlon Medical, Inc. &ldquo;Our proprietary exosome diagnostics represent a potentially powerful
addition to the liquid biopsy field. This partnership with Hoag may significantly accelerate our development of exosome based liquid
biopsies and may provide deep insights into the detection, progression and treatment options for cancer patients and their families.
We are delighted to have the opportunity to work with Dr. Demeure and the Hoag team on this project.&rdquo;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">Hoag&rsquo;s
Hereditary Cancer Program and many aspects of its cancer research are supported by philanthropy.</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">For
more information on the research studies and clinical trials at Hoag, visit&nbsp;https://www.hoag.org/specialties-services/other-programs-services/clinical-research/available-clinical-trials/.</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)"><B>ABOUT
HOAG MEMORIAL HOSPITAL PRESBYTERIAN</B></P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">Hoag
is an approximately $1 billion nonprofit, regional health care delivery network in Orange County, California, that treats
more than 30,000 inpatients and 450,000 outpatients annually. Hoag consists of two acute-care hospitals &ndash; Hoag Hospital
Newport Beach, which opened in 1952, and Hoag Hospital Irvine, which opened in 2010 &ndash; in addition to eight health
centers and 11 urgent care centers. Hoag is a designated Magnet<SUP>&reg;</SUP> hospital by the American Nurses Credentialing
Center (ANCC). Hoag offers a comprehensive blend of health care services that includes five institutes providing specialized
services in the following areas: cancer, heart and vascular,&nbsp;neurosciences,&nbsp;women&rsquo;s health, and orthopedics
through Hoag&rsquo;s affiliate, Hoag Orthopedic Institute<U>, </U>which consists of an orthopedic hospital and two ambulatory
surgical centers. Hoag has been named one of the Best Regional Hospitals in the 2019 - 2020 <I>U.S. News &amp; World
Report</I>, and<I>Becker&rsquo;s Healthcare</I>&nbsp;named Hoag as one of the 2018 &ldquo;100 Great Hospitals in
America&rdquo; &ndash; a designation Hoag has received five times. For an unprecedented 23 years, residents of Orange County
have chosen Hoag as one of the county&rsquo;s best hospitals in a local newspaper survey. Visit&nbsp;www.hoag.org&nbsp;for
more information.</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0px; background-color: rgb(255, 255, 255)">#
# #</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0px; background-color: rgb(255, 255, 255)">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 400 10pt Times New Roman, Times, Serif; text-indent: 0px; background-color: rgb(255, 255, 255)">To
download the official press release, please click&nbsp;here.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>October 2, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 36%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>001-37487</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>13-3632859</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(IRS Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9635 Granite Ridge Drive, Suite 100</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Diego, California</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>92123</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Zip Code)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: 858-459-7800 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<U>see</U> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 96%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title of each class</FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Trading Symbol</FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common Stock</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AEMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 8.01</B></TD><TD><B>Other Events.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
October 3, 2019, Aethlon Medical, Inc. (the &ldquo;Company&rdquo;) announced that Nasdaq has granted the Company an extension of
time to regain compliance with the exchange&rsquo;s continued listing requirement of a minimum $2.5 million of stockholders&rsquo;
equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
extension is conditional upon the Company completing a reverse stock split and trading at or above Nasdaq&rsquo;s minimum $1.00
bid price requirement for a period of ten consecutive trading days on or before October 29, 2019. The Company is requesting stockholder
approval of the reverse stock split at its Annual Meeting of Stockholders to be held on October 14, 2019 in order to meet this
requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
the minimum bid price requirement is met by October 29, 2019, then Nasdaq has allowed until the filing of the Company&rsquo;s December
31, 2019 Report on Form 10-Q, to be filed no later than February 14, 2020, to evidence compliance with Nasdaq&rsquo;s minimum stockholders&rsquo;
equity threshold, subject to reporting to Nasdaq prior to that time on the Company&rsquo;s fund raising progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Description</U></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Releases dated October 3, 2019.</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Aethlon Medical, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: October 3, 2019</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ James B. Frakes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James B. Frakes</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 93px; width: 225px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Aethlon
Medical Receives Extension from Nasdaq to Regain</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Compliance with Continued Listing Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO (October 3, 2019) &ndash; Aethlon
Medical, Inc. (<B>Nasdaq: AEMD</B>), a therapeutic technology company focused on unmet needs in global health, announced today
that on October 2, 2019, Nasdaq granted Aethlon Medical an extension of time to regain compliance with the exchange&rsquo;s continued
listing requirement of a minimum $2.5 million of stockholders&rsquo; equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This extension is conditional upon Aethlon
Medical completing a reverse stock split and trading at or above Nasdaq&rsquo;s minimum $1.00 bid price requirement for a period
of ten consecutive trading days on or before October 29, 2019. The Company is requesting stockholder approval of the reverse stock
split at its Annual Meeting of Stockholders to be held on October 14, 2019 in order to meet this requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the minimum bid price requirement is
met by October 29, 2019, then Nasdaq has allowed until the filing of Aethlon Medical&rsquo;s December 31, 2019 Report on Form 10-Q,
to be filed no later than February 14, 2020, to evidence compliance with Nasdaq&rsquo;s minimum stockholders&rsquo; equity threshold,
subject to reporting to Nasdaq prior to that time on Aethlon Medicals&rsquo; fund raising progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc. is focused on addressing unmet needs in
global health. The Aethlon Hemopurifier&reg; is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening
viral infections. In cancer, the Hemopurifier&reg; depletes the presence of circulating tumor-derived exosomes that promote immune
suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The Hemopurifier&reg; is an FDA
designated &quot;Breakthrough Device&quot; related to the treatment of individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate
in the development or severity of the disease cancer. The Hemopurifier also holds a Breakthrough Device designation related to
life-threatening viruses that are not addressed with approved therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which
is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional
information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks
and uncertainties. Statements containing words such as &quot;may,&quot; &quot;believe,&quot; &quot;anticipate,&quot; &quot;expect,&quot;
&quot;intend,&quot; &quot;plan,&quot; &quot;project,&quot; &quot;will,&quot; &quot;projections,&quot; &quot;estimate,&quot; &ldquo;potentially&rdquo;
or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks
and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors
that may contribute to such differences include, without limitation, the Company's ability to successfully meet the minimum bid
price and minimum stockholders&rsquo; equity requirements of the Nasdaq Capital Market, or any other national securities exchange,
and other risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that
could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption &quot;Risk
Factors&quot; in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's other filings
with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. Except as may be required by law, the
Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">858-459-7800 x3300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Proxy Voting Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_002.jpg" ALT="NewCo Signature3 (002)" STYLE="height: 42px; width: 146px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">19 Old Kings Highway S. &ndash; Suite 210</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Darien, CT 06820</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Toll Free (877) 972-0090</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Banks and Brokers call collect (203) 972-9300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">info@investor-com.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<B>&nbsp;</B><P STYLE="margin: 0"></P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>October 14, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>001-37487</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>13-3632859</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(IRS Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">of incorporation)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9635 Granite Ridge Drive, Suite 100</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Diego, California</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>92123</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Zip Code)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: 858-459-7800 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<U>see</U> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 96%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title of each class</FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Trading Symbol</FONT></TD>
    <TD STYLE="width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common Stock</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AEMD</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5.07 Submission of Matters to a Vote of Security Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We held our 2019 Annual Meeting of Stockholders on October 14,
2019 (the &ldquo;Annual Meeting&rdquo;), in which our Stockholders approved the three proposals listed below and voted against
the fourth proposal. Based on the report of the Inspector of Elections for the Annual Meeting, 14,206,408 shares out of 19,941,000
shares outstanding and entitled to vote, or approximately 71.24%, were present at the meeting, in person or by proxy. The final
results for the votes regarding each proposal are set forth in the following tables. Each of these proposals is described in detail
in the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.55pt"></TD><TD STYLE="width: 18pt">1.</TD><TD>Elect six members of the Board of Directors. All of the nominees were elected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Name</B></FONT></TD>
    <TD STYLE="width: 21%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Votes For</B></FONT></TD>
    <TD STYLE="width: 18%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Votes Against</B></FONT></TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Abstentions</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #EEEEEE">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Edward G. Broenniman</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,184,665</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">761,659</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">375,170</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Guy F. Cipriani</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,825,786</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">120,538</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">378,170</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #EEEEEE">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Charles J. Fisher, Jr., MD </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,828,980</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">121,314</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">371,200</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sabrina Martucci Johnson </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,400,318</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">545,851</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">375,325</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #EEEEEE">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">T.C., Rodell, MD, FCCP</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,812,532</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">137,644</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">371,318</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chetan S. Shah, MD</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,022,279</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">131,504</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">167,711</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.55pt"></TD><TD STYLE="width: 18pt">2.</TD><TD>Ratify the appointment of Squar Milner LLP as our independent registered public accounting firm for our fiscal year ending
March 31, 2020. The resolution was approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Votes For</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Votes Against</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Abstentions</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #EEEEEE">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13,828,122</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">300,183</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">78,103</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.55pt"></TD><TD STYLE="width: 18pt">3.</TD><TD>Approve a reverse stock split of our common stock at a ratio in the range of 1-for-10 to 1-for-15, with such ratio to be determined
in the discretion of our Board of Directors and with such reverse stock split to be effected at such time and date as determined
by our Board of Directors in its sole discretion. The resolution was approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Votes For</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Votes Against</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Abstentions</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #EEEEEE">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12,490,794</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,652,922</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">62,692</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.55pt"></TD><TD STYLE="width: 18pt">4.</TD><TD>Approve the amendment and restatement of our articles of incorporation, as amended. The resolution was not approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Votes For</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Votes Against</B></FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Abstentions</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #EEEEEE">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,930,837</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">323,095</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">67,562</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">No adjournment of the Annual Meeting
was necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following approval by our stockholders of proposal number three
at the Annual Meeting, on October 14, 2019, our Board of Directors unanimously approved a reverse stock split of all issued and
outstanding shares of our common stock, at a ratio of 1-for-15, pursuant to Nevada Revised Statutes (&ldquo;NRS&rdquo;) 78.2055.
The reverse stock split was implemented at 5:00 p.m. Eastern Time thereafter, on October 14, 2019 (the &ldquo;Effective Time&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The terms of the reverse stock split are such that every 15
shares of the Company&rsquo;s issued and outstanding common stock will automatically be combined into one issued and outstanding
share of common stock, without any change in par value per share. As a result of the reverse stock split, proportionate adjustments
will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding
stock options, restricted stock units and warrants, which will result in a proportional decrease in the number of shares of the
Company&rsquo;s common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock units and warrants,
and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants.
In addition, the number of shares reserved for issuance under the Company&rsquo;s equity compensation plans immediately prior to
the Effective Time will be reduced proportionately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No fractional shares will be issued in connection with the reverse
stock split. Stockholders will be issued one whole share of common stock in exchange for any fractional interest that such stockholder
would have otherwise received as a result of the reverse stock split. The reverse stock split will affect all stockholders proportionately
and will not affect any stockholder&rsquo;s percentage ownership of the Company&rsquo;s common stock, except to the extent that
the reverse stock split results in any stockholder owning an additional share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s common stock will begin trading on a split-adjusted
basis commencing upon market opening on The Nasdaq Capital Market on October 15, 2019. The new CUSIP number for the Company&rsquo;s
common stock following the reverse stock split is 00808Y307.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 14,
2019, the Company issued a press release announcing the reverse stock split. A copy of that press release is attached as Exhibit
99.1 hereto and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>(d) Exhibits.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 12%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 87%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release dated October 14, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Aethlon Medical, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: October 14, 2019</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 51%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ James B. Frakes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James B. Frakes</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Aethlon Announces Reverse Stock Split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SAN DIEGO, Oct. 14, 2019 /PRNewswire/ -- Aethlon Medical, Inc.
(Nasdaq: AEMD) (&ldquo;Aethlon&rdquo; or the &ldquo;Company&rdquo;), a therapeutic medical device and technology company focused
on unmet needs in global health, announced today that at the annual meeting of stockholders of the Company, held October 14, 2019,
its stockholders voted to approve a proposal authorizing the Board of Directors of the Company to effect a reverse stock split
of Aethlon&rsquo;s outstanding common stock. &nbsp;Following the special meeting of stockholders, the Board of Directors approved
a 1-for-15 reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The effective time of the reverse stock split will be 5:00 p.m.
ET&nbsp;on&nbsp;October 14, 2019. &nbsp;The Company&rsquo;s shares will begin trading on a split-adjusted basis commencing upon
market opening on&nbsp;October 15, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;By approving the reverse split, Aethlon&rsquo;s stockholders
affirmatively responded to management&rsquo;s pledge to continue to maintain capital efficiency as Aethlon seeks to unlock the
value of the Hemopurifier and its other assets,&rdquo; said Timothy C. Rodell, M.D., FCCP, Interim Chief Executive Officer of Aethlon,
&ldquo;and consequently, Aethlon has taken a crucial step in preserving its Nasdaq listing and access to equity capital.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the reverse split, each 15 shares of the Company's
issued and outstanding common stock were automatically combined and converted into one issued and outstanding share of common stock,
par value&nbsp;$0.001&nbsp;per share, and there are now approximately 1.35 million shares of common stock issued and outstanding.
&nbsp;The common shares will trade under a new CUSIP number, 00808Y307, effective&nbsp;October 15, 2019, and remain listed on the&nbsp;Nasdaq
Capital Market&nbsp;under the symbol &quot;AEMD&quot;.&nbsp; All warrants to purchase common stock, stock options and restricted
stock units of the Company outstanding immediately prior to the reverse stock split have been proportionally adjusted. No fractional
shares of common stock will be issued as a result of the reverse stock split. Instead, in lieu of any fractional shares, the Company
will issue to such stockholder such additional fraction of a share as is necessary to increase such resulting fractional share
to a full share of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon&rsquo;s transfer agent, Computershare Trust Company,
N.A., is acting as the exchange agent for the reverse stock split. Computershare will provide instructions to stockholders of record
regarding the exchange of stock certificates, as applicable. Stockholders who hold their shares in brokerage accounts or &ldquo;street
name&rdquo; are not required to take any action to effect the exchange of their shares. Stockholders with questions related to
the transfer or mechanics of the reverse, may contact Computershare at 462 South Fourth Street, Suite 1600 Louisville, KY 40202
or by phone at 1-800-546-5141.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">About Aethlon and the Hemopurifier&reg;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon is focused on addressing unmet needs in global health.
The Aethlon Hemopurifier is a clinical- stage immunotherapeutic device designed to combat cancer and life-threatening viral infections.
In cancer, the Hemopurifier depletes the presence of circulating tumor-derived exosomes that promote immune suppression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These tumor derived exosomes also seed the spread of metastases
and inhibit the benefit of leading cancer therapies. The Hemopurifier&reg; is an FDA designated &quot;Breakthrough Device&quot;
related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard
of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease
cancer. The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed
with approved therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon also owns 80% of Exosome Sciences, Inc., which is focused
on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional information
can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks
and uncertainties. Statements containing words such as &quot;may,&quot; &quot;believe,&quot; &quot;anticipate,&quot; &quot;expect,&quot;
&quot;intend,&quot; &quot;plan,&quot; &quot;project,&quot; &quot;will,&quot; &quot;projections,&quot; &quot;estimate,&quot; &quot;potentially&quot;
or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks
and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These
forward-looking statements are based upon Aethlon&rsquo;s current expectations and involve assumptions that may never materialize
or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company&rsquo;s
ability to meet and maintain the minimum bid price and minimum stockholders' equity requirements of the Nasdaq Capital Market,
or any other national securities exchange, its ability to raise additional funds, the Company&rsquo;s ability to successfully complete
future studies with its Hemopurifier and other potential products and other risks. The foregoing list of risks and uncertainties
is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated
in forward-looking statements can be found under the caption &quot;Risk Factors&quot; in the Company's Annual Report on Form 10-K
for the year ended March 31, 2019, and in the Company's other filings with the Securities and Exchange Commission, including its
quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which
they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information
to reflect future events or circumstances.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer Aethlon Medical, Inc. 858-459-7800 x3300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SOURCE Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>



















<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W * # 2(  A$! Q$!_\0
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M3_$/A30GTOP'X3\*?$[3-8\2KJGC+7_#>@K]EEUO2XVA:1F U&4[ H9GJ?\
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M&XT)^>36U1>6P?YY?^"6?BGX\?LA_M7>%=<\5? 7XS>)_@C\7-,U'X!?M*>
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'M[M_UH?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" != .$# 2(  A$! Q$!_\0
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M$.A_!C]HWQ#=^*OA!?8L-#\=:R[:CK'P]*J$59VC +^%%&T(SAFB'* #(/\
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M?_!/+_@W7^"/[7'P&\$?M=_\%2/&GQC_ &C?VE/C]H:_$S4;37/B5XBTS2O
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M\(_!/X#?M/\ P3^)W[8G[3'[1=O^U)\,M#^&'B#6OB3X@&JR?#K1?#X<Q_\
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I#>@:5/CAM,T72-,8D>K1HI!]]_IQ7258HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  J )(# 2(  A$! Q$!_\0
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ML?$;QCXGT#Q*WAWP_P#\)(?%P\8>%O">/#08@$DX!568"OU/B'P^RUY]Q'#
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MKZ2D'B/7_$\CZ"->\-,T$\4OA77XHS+;*KA9&4NCHCU^B'VKXBC_ )@W@O\
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M7GP*,74B2>;'*-[1>$/VJ?VI=0\#? O]LW4?C1HUUX-^-W[<.B?LSZA^Q\?
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M_7@2_P"L :@#ZLO?VQ/B./B)XX^+OQ"^,'Q*^'WP,^%W[=;_ +&]C\&_@_\
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?HK\X_A8[_P#"L?AS\[?\B'X0_B/_ $+^G>]% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
